Trissel L., Tramonte S., Grilley B.: Visual compatibility of odansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm48.988-992, 1991
2.
Hesketh P., Murphy W., Lester E., et al: GR 38032F (GR-C507175): A novel compound effective in the prevention of acute cisplatin-induced emesis. J Clin Oncol7:700-705, 1989
3.
Carden P., Mithell S., Waters K., et al: Prevention of cyclophosphamidelcytara5ine-induced emesis with odansetron in children with leukemia. J Clin Oncol8:1531-1535, 1990
4.
Blackwell C. , Harding S.: The clinical pharmacology of odansetron . Eur J Cancer Clin Oncol25:521-524, 1989
5.
Facts and Comparisons. SL Louis, MO, Lippincott1991
6.
Glaxo Pharmaceuticals: Data on file. Research Triangle Park, NC, 1991
7.
Einhom L., Nugy C., Werner K., et al: Odansetron: A new antiemetic for patients receiving cisplatin chemotherapy. J Clin Oncol8:731-735, 1990
